 |
answer text |
<p>NHS England (NHSE) has funded the following treatments for bladder cancer from
the date of draft positive National Institute for Health and Care Excellence (NICE)
guidance in the last 12 months:</p><p>- September 2021 - Atezolizumab for untreated
PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable</p><p>- April
2022 - Avelumab for maintenance treatment of locally advanced or metastatic urothelial
cancer after platinum-based chemotherapy</p><p>- July 2022 - nivolumab for adjuvant
treatment of invasive urothelial cancer at high risk of recurrence.</p><p>The NHSE
Cancer Programme’s key approach to improving survival rates for cancer, including
bladder cancer, is earlier diagnosis. One of the principal priorities, as set out
in the NHS Long Term Plan, is to increase the proportion of cancers diagnosed at stages
one and two to 75% by 2028. The latest NHS ‘Help Us Help You’ campaign focuses on
the barriers to earlier presentation across all cancer types, and aims to address
some of the underlying challenges to earlier diagnosis. This phase of the campaign
has so far run during March and June 2022 and in both months saw 1,600% increases
in the numbers of visits to the NHS website’s cancer symptoms page. NHSE’s plans include
repeating the abdominal and urological symptoms campaign, which addresses symptoms
relevant to bladder cancer.</p>
|
|
